Fundamental and clinical evaluation of 9,3"-diacetylmidecamycin in pediatric field
Iwasaki, Y.; Iwata, S.; Kanemitsu, T.; Jozaki, K.; Hattori, H.; Wakabayashi, R.; Kojima, Y.; Sunakawa, K.; Oikawa, T.; Osano, M.; Ichihashi, Y.; Kuratsuji, T.
Japanese Journal of Antibiotics 35(2): 429-437
1982
ISSN/ISBN: 0368-2781 PMID: 6979642 Document Number: 185257
1. The dry syrup of MOM was administered orally to 17 patients mainly with heart diseases at doses of 10 mg/kg and 20 mg/kg. In 17 cases, the serum level was measured and in 4 cases, the urinary excretion rate including the metabolites of MOM. 2. The mean maximal concentrations were 0.54 mcg/ml at 30 minutes for the group of 10 mg/kg treatment and 0.33 mcg/ml at 1 hour for the group of 20 mg/kg treatment. The dose response was not observed obviously in both groups. 3. In each of the cases, the sum of excretion rates of metabolites in the 24-hour urine was about 1%. 4. MOM was administered clinically to 39 cases with respiratory tract infections and the overall efficacy rate was 85%. 5. In this study, 5 strains of S. pyogenes were isolated and the eradication rate was 60%. 6. Although severe side effects were not observed, gastrointestinal abnormalities like diarrhea and vomiting were seen in 3 cases. 7. Any pediatric patient did not refuse taking.